These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 25187406

  • 1. Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice.
    Kianmehr Z, Soleimanjahi H, Ardestani SK, Fotouhi F, Abdoli A.
    Med Microbiol Immunol; 2015 Apr; 204(2):205-13. PubMed ID: 25187406
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
    Han JE, Wui SR, Park SA, Lee NG, Kim KS, Cho YJ, Kim HJ, Kim HJ.
    Vaccine; 2012 Jun 13; 30(28):4127-34. PubMed ID: 22561312
    [Abstract] [Full Text] [Related]

  • 3. An effective DNA priming-protein boosting approach for the cervical cancer vaccination.
    Kianmehr Z, Ardestani SK, Soleimanjahi H, Farahmand B, Abdoli A, Khatami M, Akbari K, Fotouhi F.
    Pathog Dis; 2015 Mar 13; 73(2):1-8. PubMed ID: 25722486
    [Abstract] [Full Text] [Related]

  • 4. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
    Tumban E, Muttil P, Escobar CA, Peabody J, Wafula D, Peabody DS, Chackerian B.
    Vaccine; 2015 Jun 26; 33(29):3346-53. PubMed ID: 26003490
    [Abstract] [Full Text] [Related]

  • 5. Induction of cross-neutralizing antibodies by sequential immunization with heterologous papillomavirus L1VLPs and its implications for HPV prophylactic vaccines.
    Zhang T, Chen X, Liao G, Hu M, Xu J, Xu X.
    J Med Virol; 2020 Dec 26; 92(12):3750-3758. PubMed ID: 31994744
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic.
    Chen Y, Liu Y, Zhang G, Wang A, Dong Z, Qi Y, Wang J, Zhao B, Li N, Jiang M.
    Virus Res; 2016 Jul 15; 220():97-103. PubMed ID: 27107614
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Brucella abortus RB51 lipopolysaccharide influence as an adjuvant on the therapeutic efficacy of HPV16 L1 and HPV16 E7 DNA vaccines.
    Shirmohammadi M, Soleimanjahi H, Kianmehr Z, Karimi H, Kaboudanian Ardestani S.
    Iran J Basic Med Sci; 2021 Jan 15; 24(1):92-97. PubMed ID: 33643576
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
    Wu WH, Alkutkar T, Karanam B, Roden RB, Ketner G, Ibeanu OA.
    Virol J; 2015 Sep 11; 12():140. PubMed ID: 26362430
    [Abstract] [Full Text] [Related]

  • 16. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
    Jagu S, Karanam B, Wang JW, Zayed H, Weghofer M, Brendle SA, Balogh KK, Tossi KP, Roden RBS, Christensen ND.
    Vaccine; 2015 Oct 13; 33(42):5553-5563. PubMed ID: 26382603
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.